NCT07141472Completed
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
Effects of a Glucagon-like Peptide-1 (GLP-1) Booster™ on Blood Glucose, HbA1c, Insulin, Glucagon, GLP-1, GIP, and Amylin Levels, Body Weight and Body Fat in Overweight Adult Men and Women
Source: ClinicalTrials.gov · Last updated 3 Sept 2025
Brief summary (registry, in English)
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight. PURPOSE In prior study, GB was clinically shown to reduce blood sugar level, increase GLP-1 production, and help body fat loss. The purpose of this RCT study is to further assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula vs placebo, in the hope of confirming the efficacy and safety of GB. SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, this study is a randomized controlled clinical trial for a total of 26 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints (week 0, 13 and 26).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 69 (actual)
- First submitted
- 19 Aug 2025
- Start date
- 7 Jan 2025
- Primary completion date
- 15 Jul 2025
- Lead sponsor
- Lawry Han
- Diseases
- Obesity
- NCT number
- NCT07141472
What you commit to
- Study type: Interventional
- Participants enrolled: 69
- From 7 Jan 2025 to the primary completion date, 15 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Volunteers must be over the age of 18.
- Volunteers cannot be smokers.
- Volunteers cannot be currently taking a dietary supplement or prescription for weight loss.
- Exercising volunteers must maintain their regimen consistently throughout the course of the 26-week study.
- Caffeine drinking volunteers must maintain their caffeine intake consistently throughout the course of the 26-week study.
- Volunteers need to be overweight but not obese, as defined by having a BMI between 25.0 and 29.9
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alpine Bio Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.